Latest Simulations Plus (SLP) Headlines
Simulations Plus Has Returned 25.3% Since SmarTrend Recommendation (SLP)
Comtex SmarTrend(R) - Wed Mar 12, 9:26AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 25.30% as of today's recent price of $5.72.
Simulations Plus Reports Preliminary Revenues for Second Fiscal Quarter FY2014
Business Wire - Wed Mar 05, 7:01AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its second fiscal quarter of fiscal year 2014, ended February 28, 2014 (2QFY14).
Simulations Plus Shares Up 25.5% Since SmarTrend's Buy Recommendation (SLP)
Comtex SmarTrend(R) - Tue Mar 04, 5:11PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 25.52% as of today's recent price of $5.73.
Simulations Plus to work with FDA on mechanistic IVIVC modeling
M2 - Tue Mar 04, 9:23AM CST
Simulations Plus, Inc. (NASDAQ: SLP) said it has signed a five-year research collaboration agreement with the US Food and Drug Administration to work together to determine the value of mechanistic absorption modeling in developing predictive and robust in vitro-in vivo correlations.
Simulations Plus Signs Research Collaboration Agreement with FDA
Business Wire - Mon Mar 03, 7:00AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, announced that it has signed a five-year research collaboration agreement (RCA) with the U.S. Food and Drug Administration (FDA) to work together to determine the value of mechanistic absorption modeling ("MAM") in developing predictive and robust in vitro-in vivo correlations (IVIVCs). The collaboration will examine how the use of MAM can provide additional insight and greater accuracy with regards to prediction of complex drug absorption characteristics. The ultimate goal is to facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches.
32.5% Return Seen to Date on SmarTrend Simulations Plus Call (SLP)
Comtex SmarTrend(R) - Tue Feb 25, 11:04AM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 32.53% as of today's recent price of $6.05.
Simulations Plus Up 30.8% Since SmarTrend Uptrend Call (SLP)
Comtex SmarTrend(R) - Tue Feb 18, 9:43AM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 30.78% as of today's recent price of $5.97.
Simulations Plus declares USD0.05 dividend
M2 - Fri Feb 07, 8:31AM CST
Simulations Plus, Inc. (NASDAQ: SLP) said its board of directors has decided to distribute a USD0.05 per share cash dividend in February.
Simulations Plus Announces Quarterly Cash Dividend
Business Wire - Wed Feb 05, 7:00AM CST
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a $0.05 per share cash dividend in February.
Deal Or No Deal: 5 Very Profitable Dividend Stocks Under 10 Dollars
at The Street - Tue Feb 04, 4:20PM CST
James Dennin, Kapitall: Today's screen of stocks under 10 dollars looks for plays with dividend yields and extremely high ROE. [...]
Is This the Top for Simulations Plus (SLP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 5:13AM CST
Is This the Top for Simulations Plus (SLP)?
Uptrend Call Working As Simulations Plus Stock Rises 24.9% (SLP)
Comtex SmarTrend(R) - Fri Jan 31, 5:14PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 8 months, Simulations Plus has returned 24.86% as of today's recent price of $5.70.
Simulations Plus to Present at the Sidoti Semi-Annual New York Micro-Cap Conference
Business Wire - Thu Jan 09, 8:14AM CST
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that Walt Woltosz, chairman and chief executive officer, will present at the Sidoti & Company Semi-Annual New York Micro-Cap Conference at 2:10 p.m. Eastern Time on Monday, January 13, 2014, in Estate 3 at the Grand Hyatt New York Hotel.
Simulations Plus Sets Date for 1st Quarter 2014 Earnings Release and Conference Call
Business Wire - Thu Jan 09, 6:59AM CST
Simulations Plus, Inc. (Nasdaq:SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the first quarter of its 2014 fiscal year, ended November 30, 2013, with the U.S. Securities and Exchange Commission on Monday, January 13, 2014. Chairman and Chief Executive Officer Walt Woltosz will host a conference call to discuss the Company's performance today, Thursday, January 9, at 1:15 p.m. PT/4:15 p.m. ET.
Simulations Plus Reports First-Quarter FY2014 Financial Results
Business Wire - Thu Jan 09, 6:59AM CST
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2014 ended November 30, 2013 (1QFY14).
Growing Focus on Reducing Drug Development Costs to Drive the Market for Biosimulation, According to a New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Tue Jan 07, 8:51AM CST
Follow us on LinkedIn - Growing instances of drug failures in late stage clinical trials is throwing the spotlight on biosimulation. Defined as the use of computers to simulate biological processes, biosimulation is growing in popularity with pharmaceutical companies stepping up investments in this space. Key factors driving adoption of biosimulation tools and solutions among drug developers include growing regulatory, competitive, and budgetary pressures. Broader adoption of pharmacokinetic, and pharmacodynamic modelling in pre-clinical drug discovery is also expected to drive growth in the market.
Faruqi & Faruqi, LLP Launches An Investigation Against Simulations Plus, Inc. (SLP) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Business Wire - Fri Dec 27, 1:30PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ:SLP) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval to amend the Company's 2007 Stock Option Plan.
Simulations Plus Has Returned 25.3% Since SmarTrend Recommendation (SLP)
Comtex SmarTrend(R) - Wed Mar 12, 9:26AM CDT
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 25.30% as of today's recent price of $5.72.
Simulations Plus Reports Preliminary Revenues for Second Fiscal Quarter FY2014
Business Wire - Wed Mar 05, 7:01AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its second fiscal quarter of fiscal year 2014, ended February 28, 2014 (2QFY14).
Simulations Plus Shares Up 25.5% Since SmarTrend's Buy Recommendation (SLP)
Comtex SmarTrend(R) - Tue Mar 04, 5:11PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 25.52% as of today's recent price of $5.73.
Simulations Plus to work with FDA on mechanistic IVIVC modeling
M2 - Tue Mar 04, 9:23AM CST
Simulations Plus, Inc. (NASDAQ: SLP) said it has signed a five-year research collaboration agreement with the US Food and Drug Administration to work together to determine the value of mechanistic absorption modeling in developing predictive and robust in vitro-in vivo correlations.
Simulations Plus Signs Research Collaboration Agreement with FDA
Business Wire - Mon Mar 03, 7:00AM CST
Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, announced that it has signed a five-year research collaboration agreement (RCA) with the U.S. Food and Drug Administration (FDA) to work together to determine the value of mechanistic absorption modeling ("MAM") in developing predictive and robust in vitro-in vivo correlations (IVIVCs). The collaboration will examine how the use of MAM can provide additional insight and greater accuracy with regards to prediction of complex drug absorption characteristics. The ultimate goal is to facilitate drug and generic product development by decreasing the regulatory burden through adequate modeling approaches.
32.5% Return Seen to Date on SmarTrend Simulations Plus Call (SLP)
Comtex SmarTrend(R) - Tue Feb 25, 11:04AM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 32.53% as of today's recent price of $6.05.
Simulations Plus Up 30.8% Since SmarTrend Uptrend Call (SLP)
Comtex SmarTrend(R) - Tue Feb 18, 9:43AM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 9 months, Simulations Plus has returned 30.78% as of today's recent price of $5.97.
Simulations Plus declares USD0.05 dividend
M2 - Fri Feb 07, 8:31AM CST
Simulations Plus, Inc. (NASDAQ: SLP) said its board of directors has decided to distribute a USD0.05 per share cash dividend in February.
Simulations Plus Announces Quarterly Cash Dividend
Business Wire - Wed Feb 05, 7:00AM CST
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute a $0.05 per share cash dividend in February.
Deal Or No Deal: 5 Very Profitable Dividend Stocks Under 10 Dollars
at The Street - Tue Feb 04, 4:20PM CST
James Dennin, Kapitall: Today's screen of stocks under 10 dollars looks for plays with dividend yields and extremely high ROE. [...]
Is This the Top for Simulations Plus (SLP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 03, 5:13AM CST
Is This the Top for Simulations Plus (SLP)?
Uptrend Call Working As Simulations Plus Stock Rises 24.9% (SLP)
Comtex SmarTrend(R) - Fri Jan 31, 5:14PM CST
SmarTrend identified an Uptrend for Simulations Plus (NASDAQ:SLP) on June 4th, 2013 at $4.57. In approximately 8 months, Simulations Plus has returned 24.86% as of today's recent price of $5.70.
Simulations Plus to Present at the Sidoti Semi-Annual New York Micro-Cap Conference
Business Wire - Thu Jan 09, 8:14AM CST
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that Walt Woltosz, chairman and chief executive officer, will present at the Sidoti & Company Semi-Annual New York Micro-Cap Conference at 2:10 p.m. Eastern Time on Monday, January 13, 2014, in Estate 3 at the Grand Hyatt New York Hotel.
Simulations Plus Sets Date for 1st Quarter 2014 Earnings Release and Conference Call
Business Wire - Thu Jan 09, 6:59AM CST
Simulations Plus, Inc. (Nasdaq:SLP), a leading provider of software and consulting services for pharmaceutical R&D and environmental toxicology, announced that it expects to file its quarterly report on Form 10-Q for the first quarter of its 2014 fiscal year, ended November 30, 2013, with the U.S. Securities and Exchange Commission on Monday, January 13, 2014. Chairman and Chief Executive Officer Walt Woltosz will host a conference call to discuss the Company's performance today, Thursday, January 9, at 1:15 p.m. PT/4:15 p.m. ET.
Simulations Plus Reports First-Quarter FY2014 Financial Results
Business Wire - Thu Jan 09, 6:59AM CST
Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its first quarter of fiscal year 2014 ended November 30, 2013 (1QFY14).
Growing Focus on Reducing Drug Development Costs to Drive the Market for Biosimulation, According to a New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Tue Jan 07, 8:51AM CST
Follow us on LinkedIn - Growing instances of drug failures in late stage clinical trials is throwing the spotlight on biosimulation. Defined as the use of computers to simulate biological processes, biosimulation is growing in popularity with pharmaceutical companies stepping up investments in this space. Key factors driving adoption of biosimulation tools and solutions among drug developers include growing regulatory, competitive, and budgetary pressures. Broader adoption of pharmacokinetic, and pharmacodynamic modelling in pre-clinical drug discovery is also expected to drive growth in the market.
Faruqi & Faruqi, LLP Launches An Investigation Against Simulations Plus, Inc. (SLP) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Business Wire - Fri Dec 27, 1:30PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Simulations Plus, Inc. ("Simulations Plus" or the "Company") (NASDAQ:SLP) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval to amend the Company's 2007 Stock Option Plan.
